References
1. Petersen, J., et al., A model to predict the risk of aspirin/non-steroidal anti-inflammatory drugs-related upper gastrointestinal bleeding for the individual patient. Basic Clin Pharmacol Toxicol, 2020. 126(5): p. 437-443.
2. Lee, M.W. and P.O. Katz, Nonsteroidal Antiinflammatory Drugs, Anticoagulation, and Upper Gastrointestinal Bleeding. Clin Geriatr Med, 2021. 37(1): p. 31-42.
3. Lanas, A. and C.J. Gargallo, Management of low-dose aspirin and clopidogrel in clinical practice: a gastrointestinal perspective. J Gastroenterol, 2015. 50(6): p. 626-37.
4. Lenti, M.V., et al., Mortality rate and risk factors for gastrointestinal bleeding in elderly patients. Eur J Intern Med, 2019. 61: p. 54-61.
5. Griffin, M.R., Epidemiology of nonsteroidal anti-inflammatory drug-associated gastrointestinal injury. Am J Med, 1998. 104(3a): p. 23S-29S; discussion 41S-42S.
6. de Groot, N.L., et al., Primary non-variceal upper gastrointestinal bleeding in NSAID and low-dose aspirin users: development and validation of risk scores for either medication in two large Dutch cohorts. Journal of Gastroenterology, 2014. 49(2): p. 245-253.
7. Solomon, D.H., et al., Derivation and Validation of a Major Toxicity Risk Score Among Nonsteroidal Antiinflammatory Drug Users Based on Data from a Randomized Controlled Trial. Arthritis Rheumatol, 2019. 71(8): p. 1225-1231.
8. Lee, S., et al., Impact of Preventive Strategies on Gastrointestinal Complications in Elderly Patients on Concomitant Use of Oral Anticoagulants and Nonsteroidal Anti-Inflammatory Drugs: A Nationwide Cohort Study. Drug Saf, 2022. 45(3): p. 297-304.
9. Park, E.S., et al., Venous Thromboembolism in Children and Young Adults in Korea: Analysis of the Korean Health Insurance Review and Assessment Service Database. J Korean Med Sci, 2019. 34(49): p. e316.
10. ATC/DDD Index 2021. 2021.
11. Masclee, G.M., et al., Risk of upper gastrointestinal bleeding from different drug combinations. Gastroenterology, 2014. 147(4): p. 784-792.e9; quiz e13-4.
12. Kim, T.J., et al., Effectiveness of acid suppressants and other mucoprotective agents in reducing the risk of occult gastrointestinal bleeding in nonsteroidal anti-inflammatory drug users. Sci Rep, 2019. 9(1): p. 11696.
13. Hong, W., et al., Development and validation of a risk prediction score for severe acute pancreatitis. Journal of Translational Medicine, 2019. 17(1): p. 146.
14. Schöning, V., et al., Development and validation of a prognostic COVID-19 severity assessment (COSA) score and machine learning models for patient triage at a tertiary hospital. J Transl Med, 2021. 19(1): p. 56.
15. Ajnakina, O., et al., Development and validation of prediction model to estimate 10-year risk of all-cause mortality using modern statistical learning methods: a large population-based cohort study and external validation. BMC Med Res Methodol, 2021. 21(1): p. 8.
16. Rücker, G. and M. Schumacher, Summary ROC curve based on a weighted Youden index for selecting an optimal cutpoint in meta-analysis of diagnostic accuracy. Stat Med, 2010. 29(30): p. 3069-78.
17. Krishnan, J.A., et al., Biomarkers to Predict Response to ICS and LAMA in Adolescents and Adults with Mild Persistent Asthma. Ann Am Thorac Soc, 2021.
18. Kamada, T., et al., Evidence-based clinical practice guidelines for peptic ulcer disease 2020. J Gastroenterol, 2021. 56(4): p. 303-322.
19. Lanza, F.L., F.K. Chan, and E.M. Quigley, Guidelines for prevention of NSAID-related ulcer complications. Am J Gastroenterol, 2009. 104(3): p. 728-38.
20. Kim, W.-Y., et al., Underutilization of gastrointestinal prophylaxis in high-risk chronic nonsteroidal anti-inflammatory drug users in Korea. International Journal of Clinical Pharmacy, 2021. 43(3): p. 645-653.
21. Claxton, J.S., et al., A new model to predict major bleeding in patients with atrial fibrillation using warfarin or direct oral anticoagulants. PLoS One, 2018. 13(9): p. e0203599.
22. Glasheen, W.P., et al., Charlson Comorbidity Index: ICD-9 Update and ICD-10 Translation. Am Health Drug Benefits, 2019. 12(4): p. 188-197.
Table Legends
Table 1. Baseline characteristics of the derivation and validation cohort.
Table 2. The risk score for NSAID users.
Table 3. Model discrimination by derivation and validation cohorts.
Table 4. Accuracy of the risk prediction model using the cut-off values.
Figure Legends
Fig 1. Flowchart of selection of the study population.